[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
The review gives and analyzes the data of a number of studies evaluating the safety and efficacy of nonsteroidal anti-inflammatory drugs on the upper gastrointestinal tract. Particular emphasis is laid on the results of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program. The randomized MEDAL study has shown that etoricoxib has more benefits than diclofenac.
Alekseeva
L I
LI
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004008:Diclofenac / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077613:Etoricoxib; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011725:Pyridines; D013450:Sulfones; D004008:Diclofenac; D000077613:Etoricoxib